Ifinatamab deruxtecan
Based on 1 Customer Validation
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
For research use only. We do not sell to patients.
- Purity : 98.98%
- CAS No.: 2484870-92-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[2]|
Topoisomerase I |
In Vitro
Ifinatamab deruxtecan inhibits the growth of B7-H3-expressing cancer cells in vitro, but not of B7-H3-negative cancer cells[1].
Ifinatamab deruxtecan (6 days) potently and selectively inhibits the growth of B7-H3-expressing RH-41 and MFE-280 cancer cells in vitro, with no activity against B7-H3-negative CCRF-CEM cells[2].
Ifinatamab deruxtecan (10 μg/mL; 72 hours) induces DNA damage and apoptosis in B7-H3-expressing RH-41 cancer cells in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human rhabdomyosarcoma (RH-41) cells
-
Concentration:10 μg/mL
-
Incubation Time:72 h
-
Result:Induced phosphorylation of Chk1 (a DNA damage marker) in RH-41 cells. Induced cleavage of PARP (an apoptosis marker) in RH-41 cells.
Parmacokinetics
In Vivo
Ifinatamab deruxtecan (0.3-3 mg/kg; i.v.; days 0 and 14) exerts potent antitumor activity against endometrial adenocarcinoma xenografts in mice, achieving 67% TGI at 0.3 mg/kg and complete tumor growth inhibition (100% TGI) at 1 mg/kg and 3 mg/kg[2].
Ifinatamab deruxtecan (1-10 mg/kg; i.v.; days 0 and 14) exerts potent dose-dependent antitumor activity against lung adenocarcinoma xenografts in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CAnN.Cg-Foxn1nu/CrlCrlj (lung adenocarcinoma xenograft model)[2]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.v.; days 0 and 14
-
Result:Achieved tumor growth inhibition (TGI) of 71% at 1 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 95% at 3 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 99% at 10 mg/kg compared to vehicle control group (P < 0.001).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2484870-92-8
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Ifinatamab deruxtecan]
-
Synonyms
DS-7300a; MABX-9001a; I-DXd
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[2]. Yamato M, et al. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Mol Cancer Ther. 2022;21(4):635-646. [Content Brief]
[4]. Rudin CM, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol. 2026;44(4):261-273. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ifinatamab deruxtecan
- 2484870-92-8
- DS-7300a
- MABX-9001a
- I-DXd
- Antibody-Drug Conjugates (ADCs)
- Topoisomerase
- Apoptosis
- CD276/B7-H3
- cynomolgus monkeys
- metastatic castration-resistant prostate cancer
- patient-derived xenograft mouse models
- B7-H3-expressing solid tumors
- rats
- tumor xenograft
- apoptosis
- B7-H3 (CD276)
- cancer cells
- DNA topoisomerase I
- Inhibitor
- inhibitor
- inhibit